1jh1

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 4: Line 4:
==Overview==
==Overview==
-
We describe a new generation of heterocyclic nonpeptide matrix, metalloproteinase (MMP) inhibitors derived from a 6H-1,3,4-thiadiazine, scaffold. A screening effort was utilized to identify some chiral, 6-methyl-1,3,4-thiadiazines that are weak inhibitors of the catalytic, domain of human neutrophil collagenase (cdMMP-8). Further optimization of, the lead compounds revealed general design principles that involve the, placement of a phenyl or thienyl group at position 5 of the thiadiazine, ring, to improve unprimed side affinity; the incorporation of an amino, group at position 2 of the thiadiazine ring as the chelating agent for the, catalytic zinc; the placement of a N-sulfonamide-substituted amino acid, residue at the amino group, to improve primed side affinity; and the, attachment of diverse functional groups at position 4 or 5 of the phenyl, or thienyl group at the unprimed side, to improve selectivity. The new, compounds were assayed against eight different matrix metalloproteinases, MMP-1, cdMMP-2, cdMMP-8, MMP-9, cdMMP-12, cdMMP-13, cdMMP-14, and the, ectodomain of MMP-14, respectively. A unique combination of the, above-described modifications produced the selective inhibitor, (2R)-N-[5-(4-bromophenyl)-6H-1,3,4-thiadiazin-2-yl]-2-[(phenylsulfonyl)ami, no]propanamide with high affinity for MMP-9 (K(i) = 40 nM). X-ray, crystallographic data obtained for cdMMP-8 cocrystallized with, N-allyl-5-(4-chlorophenyl)-6H-1,3,4-thiadiazin-2-amine hydrobromide gave, detailed design information on binding interactions for thiadiazine-based, MMP inhibitors.
+
We describe a new generation of heterocyclic nonpeptide matrix metalloproteinase (MMP) inhibitors derived from a 6H-1,3,4-thiadiazine scaffold. A screening effort was utilized to identify some chiral 6-methyl-1,3,4-thiadiazines that are weak inhibitors of the catalytic domain of human neutrophil collagenase (cdMMP-8). Further optimization of the lead compounds revealed general design principles that involve the placement of a phenyl or thienyl group at position 5 of the thiadiazine ring, to improve unprimed side affinity; the incorporation of an amino group at position 2 of the thiadiazine ring as the chelating agent for the catalytic zinc; the placement of a N-sulfonamide-substituted amino acid residue at the amino group, to improve primed side affinity; and the attachment of diverse functional groups at position 4 or 5 of the phenyl or thienyl group at the unprimed side, to improve selectivity. The new compounds were assayed against eight different matrix metalloproteinases, MMP-1, cdMMP-2, cdMMP-8, MMP-9, cdMMP-12, cdMMP-13, cdMMP-14, and the ectodomain of MMP-14, respectively. A unique combination of the above-described modifications produced the selective inhibitor (2R)-N-[5-(4-bromophenyl)-6H-1,3,4-thiadiazin-2-yl]-2-[(phenylsulfonyl)ami no]propanamide with high affinity for MMP-9 (K(i) = 40 nM). X-ray crystallographic data obtained for cdMMP-8 cocrystallized with N-allyl-5-(4-chlorophenyl)-6H-1,3,4-thiadiazin-2-amine hydrobromide gave detailed design information on binding interactions for thiadiazine-based MMP inhibitors.
==About this Structure==
==About this Structure==
Line 16: Line 16:
[[Category: Brandstetter, H.]]
[[Category: Brandstetter, H.]]
[[Category: Henke, A.]]
[[Category: Henke, A.]]
-
[[Category: Pfeiffer, W.D.]]
+
[[Category: Pfeiffer, W D.]]
[[Category: Schroder, J.]]
[[Category: Schroder, J.]]
[[Category: Stammler, A.]]
[[Category: Stammler, A.]]
-
[[Category: Stammler, H.G.]]
+
[[Category: Stammler, H G.]]
[[Category: Tschesche, H.]]
[[Category: Tschesche, H.]]
[[Category: Wenzel, H.]]
[[Category: Wenzel, H.]]
Line 29: Line 29:
[[Category: thiadiazine]]
[[Category: thiadiazine]]
-
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Fri Feb 15 16:07:24 2008''
+
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 13:22:34 2008''

Revision as of 11:22, 21 February 2008


1jh1, resolution 2.7Å

Drag the structure with the mouse to rotate

Crystal Structure of MMP-8 complexed with a 6H-1,3,4-thiadiazine derived inhibitor

Overview

We describe a new generation of heterocyclic nonpeptide matrix metalloproteinase (MMP) inhibitors derived from a 6H-1,3,4-thiadiazine scaffold. A screening effort was utilized to identify some chiral 6-methyl-1,3,4-thiadiazines that are weak inhibitors of the catalytic domain of human neutrophil collagenase (cdMMP-8). Further optimization of the lead compounds revealed general design principles that involve the placement of a phenyl or thienyl group at position 5 of the thiadiazine ring, to improve unprimed side affinity; the incorporation of an amino group at position 2 of the thiadiazine ring as the chelating agent for the catalytic zinc; the placement of a N-sulfonamide-substituted amino acid residue at the amino group, to improve primed side affinity; and the attachment of diverse functional groups at position 4 or 5 of the phenyl or thienyl group at the unprimed side, to improve selectivity. The new compounds were assayed against eight different matrix metalloproteinases, MMP-1, cdMMP-2, cdMMP-8, MMP-9, cdMMP-12, cdMMP-13, cdMMP-14, and the ectodomain of MMP-14, respectively. A unique combination of the above-described modifications produced the selective inhibitor (2R)-N-[5-(4-bromophenyl)-6H-1,3,4-thiadiazin-2-yl]-2-[(phenylsulfonyl)ami no]propanamide with high affinity for MMP-9 (K(i) = 40 nM). X-ray crystallographic data obtained for cdMMP-8 cocrystallized with N-allyl-5-(4-chlorophenyl)-6H-1,3,4-thiadiazin-2-amine hydrobromide gave detailed design information on binding interactions for thiadiazine-based MMP inhibitors.

About this Structure

1JH1 is a Single protein structure of sequence from Homo sapiens with , and as ligands. Active as Neutrophil collagenase, with EC number 3.4.24.34 Full crystallographic information is available from OCA.

Reference

Structure-based design and synthesis of potent matrix metalloproteinase inhibitors derived from a 6H-1,3,4-thiadiazine scaffold., Schroder J, Henke A, Wenzel H, Brandstetter H, Stammler HG, Stammler A, Pfeiffer WD, Tschesche H, J Med Chem. 2001 Sep 27;44(20):3231-43. PMID:11563922

Page seeded by OCA on Thu Feb 21 13:22:34 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Personal tools